Equity-Method Investment and Other Investments - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jul. 30, 2021
Schedule of Equity Method Investments [Line Items]
Loss from equity method investment		$ (3,857)	$ (1,834)	$ (10,905)	$ (7,831)
Equity method investment		17,166		17,166		$ 32,455
Preferred Stock Purchase Agreement [Member] | Joint Venture AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage							33.33%
Preferred Stock Purchase Agreement [Member] | Cellex and BXLS [Member] | Joint Venture AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage							66.67%
AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value							$ 62,900
Investments in and Advances to Affiliates, at Fair Value, Gross Reductions		3,700		8,700
Loss from equity method investment		1,000		6,600
Equity method investment		17,200		17,200
Sparing Vision [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value	$ 14,800
Sparing Vision [Member] | Series A2 Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	83,316
Kyverna Therapeutics Inc [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value		$ 10,000		$ 10,000
Kyverna Therapeutics Inc [Member] | Series B Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Sale of Stock, Number of Shares Issued in Transaction				3,739,515
Fair value of stock received				$ 7,000
Number of stock additionally invested				1,602,649
Cash consideration received on sale of common stock				$ 3,000